Silverleafe Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

Silverleafe Capital Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,318	Closed	-$916K	–	101
2025 Q3	$916K	Hold	20,318	–	–	0.28%	39
2025 Q2	$941K	Hold	20,318	–	–	0.33%	35
2025 Q1	$1.24M	Hold	20,318	–	–	0.43%	36
2024 Q4	$1.15M	Hold	20,318	–	–	0.36%	41
2024 Q3	$1.05M	Sell	20,318 -30	-0.1%	-$1.41K	0.36%	42
2024 Q2	$845K	Buy	+20,348	New	+$910K	0.29%	40

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Silverleafe Capital Partners's BMY Position: Q4 2025 in Review

Silverleafe Capital Partners sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 20,318 shares — an estimated $916K sold.

Silverleafe Capital Partners first reported a position in BMY in Q2 2024 and held it in 6 quarters. The position peaked at $1.24M in Q1 2025. 2,456 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

Silverleafe Capital Partners reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
Silverleafe Capital Partners sold 20,318 Bristol-Myers Squibb shares in Q4 2025, an estimated $916K.
Silverleafe Capital Partners first reported a position in Bristol-Myers Squibb in Q2 2024 and held it in 6 quarters.
Silverleafe Capital Partners's Bristol-Myers Squibb position peaked at $1.24M in Q1 2025.
2,456 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Silverleafe Capital Partners's 13F filing for Q4 2025, filed 12 Jan 2026.